Budget Bill Eases IRA Price Controls, but Coverage Losses Will Impact Pharma
-
Jul 10, 2025
The budget reconciliation legislation making President Donald Trump’s 2017 tax cuts permanent and sharply reducing federal spending in Medicaid and the Affordable Care Act insurance market provides drug manufacturers some relief from Medicare price controls established by the Inflation Reduction Act (IRA).
Manufacturers also will benefit from the bill’s tax provisions, which include a policy allowing for immediate expensing of domestic research and development spending through 2029.
Read more© 2025 MMIT
